APRIL 2024

• Valbenazine Tosylate Capsules 40 mg (base) and 80 mg (base)
  Approved: April 5, 2024 – Lupin Pharmaceuticals, Inc.
  Treatment for: Huntington’s Disease, Tardive Dyskinesia
  Generic for: Ingrezza
• Eribulin Mesylate Intravenous Solution 1 mg/2 mL (0.5 mg/mL)
  Approved: April 5, 2024 – Gland Pharma Limited
  Treatment for: Breast Cancer, Liposarcoma
  Generic for: Halaven
• Doxycycline (Anhydrous) Immediate/Delayed Release Capsules 40 mg
  Approved: April 8, 2024 – Dr. Reddys Laboratories Inc.; Lupin Pharmaceuticals, Inc.
  Treatment for: Rosacea
  Generic for: Oracea
• Estradiol Transdermal Gel (Metered) 0.06% (1.25 g/activation)
  Approved: April 22, 2024 – Solaris Pharma Corporation
  Treatment for: Menopausal Symptoms
  Generic for: EstroGel
• Deflazacort Oral Suspension 22.75 mg/mL
  Approved: April 25, 2024 – Tris Pharma Inc.
  Treatment for: Duchenne Muscular Dystrophy
  Generic for: Emflaza Suspension
• Midostaurin Capsules 25 mg
  Approved: April 29, 2024 – Teva Pharmaceuticals USA, Inc.
  Treatment for: Acute Myeloid Leukemia, Systemic Mastocytosis
  Generic for: Rydapt